- OrphanDC Gains Exclusive Rights to Commercialize QRX003 in Key Countries in Latin America
- Fourth Distribution Partnership Established Since Going Public in October 2021
- Additional Territories in Discussion
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that its wholly-owned subsidiary, Quoin Pharmaceuticals, Inc., has entered into an exclusive Distribution Agreement with OrphanDC, a partner for biotech companies in Latin America, for QRX003, the Company’s investigational treatment for Netherton Syndrome, a rare and devastating genetic disease for which there is currently no available treatment or cure.
Under the terms of the agreement, OrphanDC gains exclusive rights to commercialize QRX003 in Brazil, Argentina, and Colombia under a revenue sharing partnership. Quoin will be the exclusive supplier of QRX003 to OrphanDC.
Dr. Michael Myers, Chief Executive Officer of Quoin, commented, “We’re excited to announce Quoin’s fourth distribution agreement for QRX003. This agreement with OrphanDC covers Brazil, Argentina, and Colombia, which are the key markets in Latin America for rare and orphan diseases. OrphanDC has a tremendous track record of delivering orphan drugs to rare disease patients, and we look forward to working with them to bring relief to patients suffering with Netherton Syndrome.”
“This agreement follows the announcements of three others over the past three months that cover the Middle East and North Africa, Russia and the CIS countries, and Australia and New Zealand. We are in discussions with other international distributors as well, as we continue working diligently on all fronts to advance our clinical program,” concluded Dr. Myers.
About Netherton Syndrome
Netherton Syndrome, a form of Ichthyosis, is a rare, hereditary skin disorder caused by a mutation in the SPINK5 gene (serine protease inhibitor, Kazal Type 5) that leads to severe skin barrier defects and recurring infections, as well as a pronounced predisposition to allergies, asthma, and eczema. Patients also often suffer from severe dehydration, chronic skin inflammation and stunted growth.
Currently, there is no cure for Netherton Syndrome, nor are there any approved therapeutic treatments.
About OrphanDC
OrphanDC acts as a partner for Biotech companies in Latin America. Our local and global capabilities and expertise focus on supporting our clients from the clinical development stage throughout the product lifecycle. OrphanDC is compliant with all local and global best practices, guidelines, ethical and regulatory issues. OrphanDC offers clinical development assistance, early access programs and hosting, distribution and market access services. For more information, go to: www.orphandc.com
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is an emerging specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises three products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa and others. For more information, go to: www.quoinpharma.com.
No comments:
Post a Comment